On Fri, Nov 29, 2013 at 12:46 AM, Srihari Yamanoor <yamanoor@gmail.com> wrote:
-- This is the delicate issue - the balance of patient rights vs. commercial profit making, both of which are needed. This is not the first time the FDA has had to deal with this emotionally titillating issue. Cancer patients and their loved ones have never been able to reconcile with the stance of experimental drug administration on patients with no other available treatments (and the ethical/business issues there can be the subject of tons of PhDs).I never used 23andme as I believe genes before data is sort of a cart before horse thing, but can you expand on the "patent me" point. I am interested, even if it needs an offshoot thread.
I find the FDA is far too conservative, especially when it comes to people with no other options. But 23andme was clearly way overstepping what the data actually supported in order to make it "easy" for people.
-Katie
-- You received this message because you are subscribed to the Google Groups DIYbio group. To post to this group, send email to diybio@googlegroups.com. To unsubscribe from this group, send email to diybio+unsubscribe@googlegroups.com. For more options, visit this group at https://groups.google.com/d/forum/diybio?hl=en
Learn more at www.diybio.org
---
You received this message because you are subscribed to the Google Groups "DIYbio" group.
To unsubscribe from this group and stop receiving emails from it, send an email to diybio+unsubscribe@googlegroups.com.
To post to this group, send email to diybio@googlegroups.com.
Visit this group at http://groups.google.com/group/diybio.
To view this discussion on the web visit https://groups.google.com/d/msgid/diybio/CALY99PWXL6ZuUrDPdHzwmvOviORtmENGGyCrHizCGadHKoekoA%40mail.gmail.com.
For more options, visit https://groups.google.com/groups/opt_out.
0 comments:
Post a Comment